STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response.

Journal

Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895

Informations de publication

Date de publication:
11 Mar 2024
Historique:
received: 14 11 2023
accepted: 01 03 2024
revised: 28 02 2024
medline: 12 3 2024
pubmed: 12 3 2024
entrez: 12 3 2024
Statut: aheadofprint

Résumé

Hematopoietic stem and progenitor cells (HSPCs) maintain blood-forming and immune activity, yet intrinsic regulators of HSPCs remain elusive. STAT3 function in HSPCs has been difficult to dissect as Stat3-deficiency in the hematopoietic compartment induces systemic inflammation, which can impact HSPC activity. Here, we developed mixed bone marrow (BM) chimeric mice with inducible Stat3 deletion in 20% of the hematopoietic compartment to avoid systemic inflammation. Stat3-deficient HSPCs were significantly impaired in reconstitution ability following primary or secondary bone marrow transplantation, indicating hematopoietic stem cell (HSC) defects. Single-cell RNA sequencing of Lin

Identifiants

DOI: 10.1038/s41375-024-02218-6 PMID: 38467768
pubmed: 38467768
doi: 10.1038/s41375-024-02218-6
pii: 10.1038/s41375-024-02218-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : NCI NIH HHS
ID : R35 CA197566
Pays : United States
Organisme : NCI NIH HHS
ID : F32 CA271513
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA197566
Pays : United States

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Orkin SH, Zon LI. Hematopoiesis: an evolving paradigm for stem cell biology. Cell. 2008;132:631–44.
pubmed: 18295580 pmcid: 2628169 doi: 10.1016/j.cell.2008.01.025
Wilson A, Laurenti E, Oser G, van der Wath RC, Blanco-Bose W, Jaworski M, et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell. 2008;135:1118–29.
pubmed: 19062086 doi: 10.1016/j.cell.2008.10.048
Zhao JL, Baltimore D. Regulation of stress-induced hematopoiesis. Curr Opin Hematol. 2015;22:286.
pubmed: 26049748 pmcid: 4573392 doi: 10.1097/MOH.0000000000000149
Yamashita M, Dellorusso PV, Olson OC, Passegué E. Dysregulated haematopoietic stem cell behaviour in myeloid leukaemogenesis. Nat Rev Cancer. 2020;20:365–82.
pubmed: 32415283 pmcid: 7658795 doi: 10.1038/s41568-020-0260-3
Zon LI. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature. 2008;453:306–13.
pubmed: 18480811 doi: 10.1038/nature07038
Trowbridge JJ, Starczynowski DT. Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS. J Exp Med. 2021;218:e20201544.
pubmed: 34129017 pmcid: 8210621 doi: 10.1084/jem.20201544
Chavakis T, Mitroulis I, Hajishengallis G. Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. Nat Immunol. 2019;20:802–11.
pubmed: 31213716 pmcid: 6709414 doi: 10.1038/s41590-019-0402-5
Pietras EM. Inflammation: a key regulator of hematopoietic stem cell fate in health and disease. Blood. 2017;130:1693–8.
pubmed: 28874349 pmcid: 5639485 doi: 10.1182/blood-2017-06-780882
Bogeska R, Mikecin AM, Kaschutnig P, Fawaz M, Büchler-Schäff M, Le D, et al. Inflammatory exposure drives long-lived impairment of hematopoietic stem cell self-renewal activity and accelerated aging. Cell Stem Cell. 2022;29:1273–84.
pubmed: 35858618 pmcid: 9357150 doi: 10.1016/j.stem.2022.06.012
Hormaechea-Agulla D, Le DT, King KY. Common sources of inflammation and their impact on hematopoietic stem cell biology. Curr Stem Cell Rep. 2020;6:96–107.
pubmed: 32837857 pmcid: 7429415 doi: 10.1007/s40778-020-00177-z
Kovtonyuk LV, Caiado F, Garcia-Martin S, Manz EM, Helbling P, Takizawa H, et al. IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice. Blood. 2022;139:44–58.
pubmed: 34525198 doi: 10.1182/blood.2021011570
Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA, et al. IFNα activates dormant haematopoietic stem cells in vivo. Nature. 2009;458:904–8.
pubmed: 19212321 doi: 10.1038/nature07815
McCabe A, Zhang Y, Thai V, Jones M, Jordan MB, MacNamara KC. Macrophage-lineage cells negatively regulate the hematopoietic stem cell pool in response to interferon gamma at steady state and during infection. Stem Cells. 2015;33:2294–305.
pubmed: 25880153 doi: 10.1002/stem.2040
Matatall KA, Shen CC, Challen GA, King KY. Type-II interferon promotes differentiation of myeloid-biased hematopoietic stem cells. Stem Cells. 2014;32:3023–30.
pubmed: 25078851 doi: 10.1002/stem.1799
Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M, et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type-I interferons. J Exp Med. 2014;211:245–62.
pubmed: 24493802 pmcid: 3920566 doi: 10.1084/jem.20131043
Demerdash Y, Kain B, Essers MA, King KY. Yin and Yang: The dual effects of interferons on hematopoiesis. Exp Hematol. 2021;96:1–2.
pubmed: 33571568 pmcid: 8919039 doi: 10.1016/j.exphem.2021.02.002
Strati P, Li X, Deng Q, Marques-Piubelli ML, Henderson J, Watson G, et al. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Rep Med. 2023;4:101158.
pubmed: 37586321 pmcid: 10439270 doi: 10.1016/j.xcrm.2023.101158
Starczynowski DT, Kuchenbauer F, Argiropoulos B, Sung S, Morin R, Muranyi A, et al. Identification of miR-145 and miR-146a as mediators of the 5q–syndrome phenotype. Nat Med. 2010;16:49–58.
pubmed: 19898489 doi: 10.1038/nm.2054
Hartner JC, Walkley CR, Lu J, Orkin SH. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat. Immunol. 2009;10:109–15.
pubmed: 19060901 doi: 10.1038/ni.1680
Cheng X, Byrne M, Brown KD, Konopleva MY, Kornblau SM, Bennett RL, et al. PKR inhibits the DNA damage response, and is associated with poor survival in AML and accelerated leukemia in NHD13 mice. Blood. 2015;126:1585–94.
pubmed: 26202421 pmcid: 4582335 doi: 10.1182/blood-2015-03-635227
Hu SB, Heraud-Farlow J, Sun T, Liang Z, Goradia A, Taylor S, et al. ADAR1p150 prevents MDA5 and PKR activation via distinct mechanisms to avert fatal autoinflammation. Mol Cell. 2023;83:3869–84.
pubmed: 37797622 doi: 10.1016/j.molcel.2023.09.018
Hillmer EJ, Zhang H, Li HS, Watowich SS. STAT3 signaling in immunity. Cytokine Growth Factor Rev. 2016;31:1–5.
pubmed: 27185365 pmcid: 5050093 doi: 10.1016/j.cytogfr.2016.05.001
Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity. 1999;10:39–49.
pubmed: 10023769 doi: 10.1016/S1074-7613(00)80005-9
Chrisikos TT, Zhou Y, Kahn LM, Patel B, Denne NL, Brooks A, et al. STAT3 inhibits autocrine IFN signaling in type-I conventional dendritic cells. J Immunol. 2022;209:1286–99.
pubmed: 36038291 doi: 10.4049/jimmunol.2101104
Zhang H, Hu H, Greeley N, Jin J, Matthews AJ, Ohashi E, et al. STAT3 restrains RANK-and TLR4-mediated signalling by suppressing expression of the E2 ubiquitin-conjugating enzyme Ubc13. Nat Commun. 2014;5:5798.
pubmed: 25503582 doi: 10.1038/ncomms6798
Mantel C, Messina-Graham S, Moh A, Cooper S, Hangoc G, Fu XY, et al. Mouse hematopoietic cell–targeted STAT3 deletion: stem/progenitor cell defects, mitochondrial dysfunction, ROS overproduction, and a rapid aging–like phenotype. Blood. 2012;120:2589–99.
pubmed: 22665934 pmcid: 3460681 doi: 10.1182/blood-2012-01-404004
Melillo JA, Song L, Bhagat G, Blazquez AB, Plumlee CR, Lee C, et al. Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol. 2010;184:2638–45.
pubmed: 20124100 doi: 10.4049/jimmunol.0902960
Panopoulos AD, Zhang L, Snow JW, Jones DM, Smith AM, El Kasmi KC, et al. STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood. 2006;108:3682–90.
pubmed: 16888100 pmcid: 1895456 doi: 10.1182/blood-2006-02-003012
Zhang H, Li HS, Hillmer EJ, Zhao Y, Chrisikos TT, Hu H, et al. Genetic rescue of lineage-balanced blood cell production reveals a crucial role for STAT3 antiinflammatory activity in hematopoiesis. Proc Natl Acad Sci USA. 2018;115:E2311–9.
pubmed: 29463696 pmcid: 5878002
Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, et al. Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature. 2014;512:198–202.
pubmed: 25079315 pmcid: 4456040 doi: 10.1038/nature13619
Walter D, Lier A, Geiselhart A, Thalheimer FB, Huntscha S, Sobotta MC, et al. Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature. 2015;520:549–52.
pubmed: 25707806 doi: 10.1038/nature14131
Kalogeropoulou A, Mougkogianni M, Iliadou M, Nikolopoulou E, Flordelis S, Kanellou A, et al. Intrinsic neural stem cell properties define brain hypersensitivity to genotoxic stress. Stem Cell Rep. 2022;17:1395–410.
doi: 10.1016/j.stemcr.2022.04.018
Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol. 2002;12:1817–27.
pubmed: 12419181 doi: 10.1016/S0960-9822(02)01225-3
Pant V, Quintás-Cardama A, Lozano G. The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood. 2012;120:5118–27.
pubmed: 23018641 pmcid: 3537308 doi: 10.1182/blood-2012-05-356014
Klein B, Günther C. Type-I interferon induction in cutaneous DNA damage syndromes. Front Immunol. 2021;12:715723.
pubmed: 34381458 pmcid: 8351592 doi: 10.3389/fimmu.2021.715723
Pang Q, Christianson TA, Keeble W, Koretsky T, Bagby GC. The anti-apoptotic function of Hsp70 in the interferon-inducible double-stranded RNA-dependent protein kinase-mediated death signaling pathway requires the Fanconi anemia protein, FANCC. J Biol Chem. 2002;277:49638–43.
pubmed: 12397061 doi: 10.1074/jbc.M209386200
Piazzi M, Bavelloni A, Gallo A, Faenza I, Blalock WL. Signal transduction in ribosome biogenesis: a recipe to avoid disaster. Int J Mol Sci. 2019;20:2718.
pubmed: 31163577 pmcid: 6600399 doi: 10.3390/ijms20112718
Kaminski JJ, Schattgen SA, Tzeng TC, Bode C, Klinman DM, Fitzgerald KA. Synthetic oligodeoxynucleotides containing suppressive TTAGGG motifs inhibit AIM2 inflammasome activation. J Immunol. 2013;191:3876–83.
pubmed: 23986531 doi: 10.4049/jimmunol.1300530
Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424:516–23.
pubmed: 12872134 doi: 10.1038/nature01850
Lee MG, Han J, Jeong SI, Her NG, Lee JH, Ha TK, et al. XAF1 directs apoptotic switch of p53 signaling through activation of HIPK2 and ZNF313. Proc Natl Acad Sci USA. 2014;111:15532–7.
pubmed: 25313037 pmcid: 4217407 doi: 10.1073/pnas.1411746111
Townsend PA, Scarabelli TM, Davidson SM, Knight RA, Latchman DS, Stephanou A. STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis. J Biol Chem. 2004;279:5811–20.
pubmed: 14602726 doi: 10.1074/jbc.M302637200
Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, Nakajima K, et al. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 1998;17:6670–7.
pubmed: 9822610 pmcid: 1171012 doi: 10.1093/emboj/17.22.6670
Zhang H, Nguyen-Jackson H, Panopoulos AD, Li HS, Murray PJ, Watowich SS. STAT3 controls myeloid progenitor growth during emergency granulopoiesis. Blood. 2010;116:2462–71.
pubmed: 20581311 pmcid: 2953883 doi: 10.1182/blood-2009-12-259630
Yan D, Jobe F, Hutchison RE, Mohi G. Deletion of Stat3 enhances myeloid cell expansion and increases the severity of myeloproliferative neoplasms in Jak2V617F knock-in mice. Leukemia. 2015;29:2050–61.
pubmed: 26044284 pmcid: 4598256 doi: 10.1038/leu.2015.116
Hock H, Hamblen MJ, Rooke HM, Schindler JW, Saleque S, Fujiwara Y, et al. Gfi-1 restricts proliferation and preserves functional integrity of haematopoietic stem cells. Nature. 2004;431:1002–7.
pubmed: 15457180 doi: 10.1038/nature02994
Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, et al. p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell. 2009;4:37–48.
pubmed: 19128791 pmcid: 2839936 doi: 10.1016/j.stem.2008.11.006
Li X, Wilson AF, Du W, Pang Q. Cell-cycle-specific function of p53 in Fanconi anemia hematopoietic stem and progenitor cell proliferation. Stem Cell Rep. 2018;10:339–46.
doi: 10.1016/j.stemcr.2017.12.006
Chen S, Yu H, Kobayashi M, Gao R, Boswell HS, Liu Y. Gain-of-function mutant p53 enhances hematopoietic stem cell self-renewal. Blood. 2014;124:260.
doi: 10.1182/blood.V124.21.260.260
Bellodi C, Kopmar N, Ruggero D. Deregulation of oncogene‐induced senescence and p53 translational control in X‐linked dyskeratosis congenita. EMBO J. 2010;29:1865–76.
pubmed: 20453831 pmcid: 2885924 doi: 10.1038/emboj.2010.83
Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, et al. Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell. 2012;11:36–49.
pubmed: 22683204 pmcid: 3392433 doi: 10.1016/j.stem.2012.05.013
Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16:369–77.
pubmed: 19878869 pmcid: 4369769 doi: 10.1016/j.ccr.2009.09.024
Laouar Y, Welte T, Fu XY, Flavell RA. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity. 2003;19:903–12.
pubmed: 14670306 doi: 10.1016/S1074-7613(03)00332-7
Rouyez MC, Lestingi M, Charon M, Fichelson S, Buzyn A, Dusanter-Fourt I. IFN regulatory factor-2 cooperates with STAT1 to regulate transporter associated with antigen processing-1 promoter activity. J Immunol. 2005;174:3948–58.
pubmed: 15778351 doi: 10.4049/jimmunol.174.7.3948
Pietras EM, Mirantes-Barbeito C, Fong S, Loeffler D, Kovtonyuk LV, Zhang S, et al. Chronic interleukin-1 exposure drives haematopoietic stem cells towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell Biol. 2016;18:607–18.
pubmed: 27111842 pmcid: 4884136 doi: 10.1038/ncb3346
Thongon N, Ma F, Santoni A, Marchesini M, Fiorini E, Rose A, et al. Hematopoiesis under telomere attrition at the single-cell resolution. Nat Commun. 2021;12:6850.
pubmed: 34824242 pmcid: 8617077 doi: 10.1038/s41467-021-27206-7
Masumi A, Hamaguchi I, Kuramitsu M, Mizukami T, Takizawa K, Momose H, et al. Interferon regulatory factor-2 induces megakaryopoiesis in mouse bone marrow hematopoietic cells. FEBS Lett. 2009;583:3493–500.
pubmed: 19818776 doi: 10.1016/j.febslet.2009.10.006
Tong J, Sun T, Ma S, Zhao Y, Ju M, Gao Y, et al. Hematopoietic stem cell heterogeneity is linked to the initiation and therapeutic response of myeloproliferative neoplasms. Cell Stem Cell. 2021;28:502–13.
pubmed: 33621485 doi: 10.1016/j.stem.2021.01.018
Unterholzner L, Keating SE, Baran M, Horan KA, Jensen SB, Sharma S, et al. IFI16 is an innate immune sensor for intracellular DNA. Nat Immunol. 2010;11:997–1004.
pubmed: 20890285 pmcid: 3142795 doi: 10.1038/ni.1932
Shehata M, van Amerongen R, Zeeman AL, Giraddi RR, Stingl J. The influence of tamoxifen on normal mouse mammary gland homeostasis. Breast Cancer Res. 2014;16:1–11.
doi: 10.1186/s13058-014-0411-0
Sánchez-Aguilera A, Méndez-Ferrer S. Regulation of hematopoietic progenitors by estrogens as a basis for new antileukemic strategies. Mol Cell Oncol. 2016;3:e1009728.
pubmed: 27308525 doi: 10.1080/23723556.2015.1009728

Auteurs

Bhakti Patel (B)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Yifan Zhou (Y)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Rachel L Babcock (RL)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.

Feiyang Ma (F)

Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.
Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, University of Michigan, Ann Arbor, MI, USA.

M Anna Zal (MA)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Dhiraj Kumar (D)

Herbert Irving Cancer Center and Department of Genetics and Development, Columbia University, New York, NY, USA.
ORCID: 0000-0002-6085-5911

Yusra B Medik (YB)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Laura M Kahn (LM)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.

Josué E Pineda (JE)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.

Elizabeth M Park (EM)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Sarah M Schneider (SM)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA.
ORCID: 0000-0001-7027-7978

Ximing Tang (X)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Maria Gabriela Raso (MG)

Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Collene R Jeter (CR)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Tomasz Zal (T)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Karen Clise-Dwyer (K)

Department of Stem Cell Transplantation and Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Khandan Keyomarsi (K)

Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Filippo G Giancotti (FG)

Herbert Irving Cancer Center and Department of Genetics and Development, Columbia University, New York, NY, USA.
ORCID: 0000-0002-0541-9519

Simona Colla (S)

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
ORCID: 0000-0001-6583-8910

Stephanie S Watowich (SS)

Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. swatowic@mdanderson.org.
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USA. swatowic@mdanderson.org.
Program for Innovative Microbiome and Translational Research (PRIME-TR), The University of Texas MD Anderson Cancer Center, Houston, TX, USA. swatowic@mdanderson.org.
ORCID: 0000-0003-1969-659X

Classifications MeSH